You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • THU0228 Tofacitinib, an Oral Janus Kinase Inhibitor: Post-HOC Analyses of Efficacy and Safety of Monotherapy Versus Combination Therapy in a Phase 3 Rheumatoid Arthritis Population

Alerts

Article menu
Download PDFPDF
Poster Presentation
Rheumatoid arthritis - non biologic treatment
THU0228 Tofacitinib, an Oral Janus Kinase Inhibitor: Post-HOC Analyses of Efficacy and Safety of Monotherapy Versus Combination Therapy in a Phase 3 Rheumatoid Arthritis Population
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address